Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07501442
Starting soon Not applicable

Clinical Trial Evaluating the Efficacy and Safety of Uracil 0,5% Plasters in Oncology Patients Affected by Hand-foot Syndrome (HFS)

NCT07501442 · tracked via the Priya Life Science Italy tracker
Sponsor
Wooshin Labottach Co., Ltd
Phase
Not applicable
Started
2026-07
Last updated
2026-03-30

Condition(s) studied

HFS

Investigational drug(s) / intervention(s)

Uracil 0,5% plasterslenitive cream

Uracil 0,5% plasters: Patients will applicate to hands and feet the plaster twice per day for 3 weeks to reduce the HFS grade.

lenitive cream: Patients will applicate the cream 3 times per day for 3 weeks to compare the change of HFS severity

Study summary

The goal of this clinical trial is to learn if The Uracil plaster works to treat mild HFS in adults under chemiotherapy. It will also learn about the safety .

The main questions it aims to answer are:

Does Uracil Plaster lower the number of days participants need to reduce the HFS symptoms? What medical problems do participants have when using the Uracil plaster MD? Researchers will compare the Uracil plaster to a standard lenitive cream to see if Uracil Plaster works better to treat mild HFS.

Participants will:

Use the plaster or the cream 2/3 times day for 3 weeks Visit the hospital once every week for checkups and tests Keep a diary of their symptoms and the number of times they use the therapy

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * Both sexes; * Aged over 18 years; * Willing and able to return to the study site for post-procedural assessments; * Agree to take precautions to prevent pregnancy (applicable only to non-menopausal female subjects), including abstinence, intrauterine device (IUD), progestin implants, combined estrogen-progestin contraceptives, or condom use; * Agree to sign the informed consent form. * With HFS of grade I and II severity due to chemotherapy Self-sufficient with Performance Status of 0, 1, 2 according with the EOCG table. * Red blood cells folate test and serum folate test- Independent Biomarkers performed and to polymorphism testing DPD before starting therapy with dihydro pyrimidines. Exclusion criteria * Patients with grade III severity according to of HFS severity (Hand-Foot Syndrome- NCI-CTCAE v.0 Severity Grading. * ECOG Performance Status Scale = 3 or 4 * Pregnancy (applicable only to non-menopausal female subjects); * Breastfeeding (applicable only to non-menopausal female subjects); * Non-menopausal female subjects not using the specified contraceptive measures to prevent pregnancy during the study; * Sensitivity or allergy to the investigational product or its components (to be assessed by the investigator at baseline); * Predicted poor compliance with study protocol; * Participation in a similar study currently or within the past 3 months; * Dermatological clinical conditions that could interfere with performance outcomes; * Current pharmacological treatment with: * Medications that may affect test results as deemed by the investigator. * Use of other medications not mentioned above can be authorized by the investigator. Trade name, dosage, start and end dates of therapy will be documented in the concomitant medication form.

Primary outcome measure(s)

  • Adverse events number — 3 weeks, from the start to the end of the trial
    Number of Adverse events during the treatment
  • Complete healing of the lesions according to HFS severity scale — 3 weeks, from beginning to end of the trial
    Complete healing of the hands or feet lesions without chemotherapy dosage reduction, using HFS severity scales to assess the absence of symptoms.

Trial sites (1)

FacilityCityRegionStatus
Presidio Ospedaliero Di Rho - Asst Rhodense- Oncology Department Rho MI

More Wooshin Labottach Co., Ltd. trials in Italy

A Study to Evaluate the Safety and Clinical Performance of a Dexpanthenol Medicated Hydrogel Patch in the Treatment of Standardized Superficial Abrasions Starting soon
Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07501442 on ClinicalTrials.gov ↗ ← All trials in Italy